N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Moscow, Russia.
J Pediatr Hematol Oncol. 2021 Apr 1;43(3):90-94. doi: 10.1097/MPH.0000000000002065.
The potential of mesenchymal multipotent (stem) cells (MSC) to modify immune reactions and mediate hematopoiesis boosted great interest for their use in allogeneic hemopoietic stem cell transplantation. Because of MSC production of a wide range of cytokines and growth factors, these cells are included in the therapy of graft-versus-host disease (GVHD). A number of clinical studies have demonstrated safety and efficacy of MSC-based therapy in acute GVHD. Japan and some other countries approved biomedical cell products on the base of allogeneic bone marrow (BM) MSCs as medical agents for acute GVHD treatment. Besides, MSCs may form BM stroma and improve hematopoiesis. Simultaneous transplantation of hematopoietic stem cells and MSCs effectively improved engraftment and prevented GVHD in transplantation of umbilical cord blood and human leukocyte antigens-incompatible BM stem cells. The review presents the analysis of clinical studies of MSCs in allogeneic hematopoietic stem cell transplantation and discusses different approaches for improvement of MSC-based GVHD treatment and prophylaxis.
间充质多能（干）细胞（MSC）具有改变免疫反应和介导造血的潜力，因此人们对其在异基因造血干细胞移植中的应用产生了极大的兴趣。由于 MSC 产生广泛的细胞因子和生长因子，因此这些细胞被纳入移植物抗宿主病（GVHD）的治疗中。许多临床研究已经证明了基于 MSC 的治疗在急性 GVHD 中的安全性和有效性。日本和其他一些国家已经批准了基于同种异体骨髓（BM）MSC 的生物医学细胞产品作为治疗急性 GVHD 的药物。此外，MSC 可以形成 BM 基质并改善造血。造血干细胞和 MSC 的同时移植有效地改善了脐带血和人类白细胞抗原不相容的 BM 干细胞移植中的植入，并预防了 GVHD。本综述分析了 MSC 在异基因造血干细胞移植中的临床研究，并讨论了改善基于 MSC 的 GVHD 治疗和预防的不同方法。
